Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
Newsletters
Training
White Papers
Advertising
Contact Us
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > Strides Arcolab Receives FDA Approval for Rocuronium Bromide Injection

FDAnews Drug Daily Bulletin

Aug. 2, 2010 | Vol. 7 No. 149

Strides Arcolab Receives FDA Approval for Rocuronium Bromide Injection

Strides Arcolab announced the FDA has granted approval of rocuronium bromide 10mg/ml-5ml and 10 ml multidose vials, a nondepolarizing neuromuscular blocking agent.
BloombergUTV

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Sanofi Pitched $71 Offer to Genzyme Mylan Completes $550 Million Acquisition of Bioniche Pharma Lonza Signs Production Deal With Glaxo Onyx Pharma Gets Japanese Drug Development Deal

Home
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.